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Financing tuberculosis control: promising trends and 
remaining challenges
The ﬁ nancing of essential health services for the 
world’s poor is changing. Development assistance 
to health (DAH) seems to be ﬂ at-lining, and use of 
domestic resources and value for money are increasingly 
emphasised.1,2 Many development agencies are re-
examining thematic and geographic priorities and 
implementing new coﬁ nancing agreements. The 
Global Fund to Fight AIDS, Tuberculosis and Malaria, for 
example, now requires 5–60% counterpart ﬁ nancing, 
depending on a country’s income.3 Ensuring that scarce 
development funds ﬂ ow at a suﬃ  cient scale to eﬀ ective 
interventions that serve people who need them most 
remains a challenge.  
Much previous work highlights the rapid increases in 
DAH in the past decade,4 but in The Lancet Global Health, 
Katherine Floyd and colleagues5 report that, in the 
case of tuberculosis, growth in domestic ﬁ nancing has 
been equally impressive. Their ﬁ ndings are convincing, 
especially in view of the fact that their study might 
underestimate domestic contributions because some 
health systems expenditures and costs incurred by 
patients outside formal tuberculosis services are 
excluded. Domestic funding for tuberculosis increased 
by more than 160% in 9 years to reach US$3·9 billion 
in 2011, driven mostly by Brazil, Russia, India, China, 
and South Africa (BRICS), which, in 2011, paid for more 
than 95% of their yearly tuberculosis bills. UNAIDS 
reports a similar trend in HIV spending—BRICS increased 
domestic expenditure by more than 120% between 
2006 and 2011, and now fund more than 75% of their 
HIV responses.6 These ﬁ ndings are important and 
support the reorientation of DAH towards the poorest 
countries, although much work remains to be done to 
reduce the costs of tuberculsosis borne by poor patients 
and their families in middle-income countries.7    
This encouraging global picture needs to be balanced 
with the substantial resource gap that remains (mainly 
in low-income countries). Floyd and colleagues 
estimate that an additional $1·6–2·3 billion of DAH a 
year is needed for a comprehensive global response to 
the tuberculosis epidemic, and even this amount might 
be an underestimate. Countries might not be able to 
expand health expenditure at the same pace as general 
government expenditure, and much of the domestic 
contribution to tuberculosis services is funding for 
general health services. Core health systems can take 
time to expand because of investment constraints, 
such as the time needed to train new health workers. 
Furthermore, although costs might be reduced as 
coverage expands (economies of scale), detection 
of cases of tuberculosis that are not being reached 
through the health system and incorporation of new 
technologies might increase costs. Finally, increasing 
DAH could substitute for and reduce domestic 
funding.8 Floyd and colleagues’ data suggest that, 
in low-income and lower-middle-income countries, 
domestic funding as a proportion of total funding 
fell by 6–10%, supporting the need for coﬁ nancing 
agreements in the future.
The investment case for tuberculosis control is as 
sound as ever. The foundations are strong. Floyd and 
coworkers’ ﬁ ndings emphasise that tuberculosis services 
are highly cost-eﬀ ective, not only in trial settings, 
but also on a global scale. At a cost as low as $100 per 
patient successfully treated in high-burden countries, 
tuberculosis control remains as good value as ever. 
However, for a disease that still causes more than 
1·2 million deaths every year, funding for tuberculosis 
fares badly compared with the $16·8 billion spent on 
HIV/AIDS, which caused 1·47 million deaths in 2011.6,9 
Global and national institutions working in tuberculosis 
therefore have much to do to ensure that DAH is 
allocated on the basis of the best available evidence for 
cost-eﬀ ectiveness. Making the case for further expansion 
of treatment for multidrug-resistant tuberculosis and 
more intensive screening will not necessarily be easy. 
Although both might be cost eﬀ ective, arguing for more 
resources to expand the the package of tuberculosis 
services will be challenging for countries struggling to 
ensure eﬀ ective case detection and DOTS coverage. 
Lessons can be learned from work in HIV, in which 
increased attention is focused on the potential beneﬁ ts 
of releasing additional funding for service delivery 
through increased eﬃ  ciency.10 Floyd and colleagues 
suggest that tuberculosis costs are driven mainly by 
country income level and caseload. However, within 
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countries, cost variation in health services can be 
substantial,11 yet little is known about the extent of 
ineﬃ  ciency within tuberculosis services. Furthermore, 
in the future, new, shorter drugs regimens, if proven 
eﬃ  cacious and appropriately priced, could reduce costs 
to both the health system and patients. Although 
Floyd and colleagues should be congratulated for their 
succinct summary of the ﬁ nancing of tuberculosis 
control, much work remains to ensure that poor people 
no longer have to bear both the economic and health 
burden of this preventable and treatable disease.
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